This 2024 paper is a narrative review of cannabidiol, cannabis-derived products, regulation, pharmacology, and clinical use. It offers a useful overview of why purified CBD, commercial extracts, and broader cannabis products should not be treated as interchangeable. Its value is real, but it remains a narrative review, not a new trial, so its conclusions should be read as framing and synthesis rather than definitive proof.
Study: Cannabis Harm Reduction Strategies
This 2025 review maps cannabis harm reduction strategies across legal, social, and health-related domains, from packaging rules and driving policies to cannabis social clubs and product testing. It is useful as a typology and policy overview, but it does not establish which measures work best because the evidence base is mixed and often qualitative. For readers and clinicians, the value here is in clearer thinking about risk reduction, not in assuming these interventions are already proven.
Standardizing Recreational Cannabis Excise Tax Rates in the United States: New Retail Price-Based Measurements by Product Category.
Cannabis excise tax structures vary widely across the states in the United States. Standardizing taxes may improve cross-state comparisons and strengthen eva…
Missouri has nearly $100 million in marijuana tax revenue sitting unused, despite voter mandate
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Healthcare PolicyAccess To CareState ProgramsCannabis RegulationPublic Health Funding Why This MattersDelayed implementation of voter-mandated...
CED Regulatory Digest, Since Last Digest, 14 items
Digest covering 14 recent regulatory items.
America Doesn’t Have A ‘Marijuana Problem,’ As NYT Claims—It Has a Cannabis Education …
WHY IT MATTERS: When media and policymakers frame cannabis use as a “problem” rather than an education gap, it slows the development of clinical programs, physician training, and insurance coverage that patients need to access safe, guided care. CLINICAL OVERVIEW: The framing of cannabis as a “marijuana problem” in mainstream media reflects a deeper failure in clinical education, research access, and regulatory coherence rather than an inherent danger of the plant itself. Physicians are not trained in endocannabinoid medicine during medical school, research remains federally restricted, and patients are left navigating a fragmented system without proper clinical guidance.